Fig. 1: Intravenous injection of myelin oligodendrocyte glycoprotein (MOG)-loaded MSNs suppressed EAE development. | Nature Communications

Fig. 1: Intravenous injection of myelin oligodendrocyte glycoprotein (MOG)-loaded MSNs suppressed EAE development.

From: Immunosuppressive biomaterial-based therapeutic vaccine to treat multiple sclerosis via re-establishing immune tolerance

Fig. 1

a Transmission electron microscopy (TEM) image of MSNs, scale bar: 200 nm; the experiment was repeated independently at least three times. b Representative histograms of rhodamine B isothiocyanate (RITC) signal from splenocytes of C57BL/6 mice that were left untreated (no injection) or intravenously injected with RITC-MSNs 24 h before flow cytometry analysis. c Percentage of immune cells that engulfed RITC-MSNs in spleens, n = 4 biologically independent animals. d Schematics for MOG loading in MSNs. e EAE was induced in C57BL/6 mice before being injected intravenously with bare MSNs (MSN), MOG35–55 peptide-loaded MSNs (MSN-MOG), OVA323–339 peptide-loaded MSNs (MSN-OVA), soluble MOG (MOG), or left untreated on days 4, 7, and 10 (n = 6). f EAE clinical score for different groups of mice. g Kaplan–Meier curves demonstrating the percentage of EAE-free mice over time, P values were calculated using log-rank (Mantel–Cox) test. Data in (c) are represented as mean ± standard deviation (SD). Data in (f) are represented as mean ± standard error (SE). Data in (f) were subjected to one-way analysis of variance (ANOVA) with Dunnett’s multiple comparisons test. P < 0.05 was considered significant.

Back to article page